Three key notes:
1. Menlo Park, Calif.-based Arrinex developed ClariFix, a cryoablation technology designed to treat chronic rhinitis, which affects 24 million people in the U.S. annually.
2. Originally founded in 2013, the company started commercializing CarliFix in late 2017. The ClariFix product will expand Stryker’s ENT portfolio.
3. Stryker believes the ENT market is a large, unpenetrated segment for the company.
“The acquisition of Arrinex is highly complementary to Stryker’s ENT portfolio, which is part of our neurotechnology business,” said Stryker Group President, Neurotechnology, Instruments and Spine Spencer Stiles. “The acquisition aligns with our focus on providing ENT physicians with new technologies that deliver more treatment options and better patient outcomes.”
More articles on orthopedic devices:
21 spine devices receive FDA 510(k) clearance in January
Medtronic reports $7.5B in Q3 revenue & more: 12 device company notes
4 things to know about pedicle screw design
